Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
A paradox in tumor immunity is the co-existing of growing tumors with circulating or tissue-infiltrating tumor-reactive T cells. The inability of tumor-reactive T cells in control of tumor growth has been attributed to the presence of regulatory T cells (Treg) in cancer host. Since then, understanding the role of Treg cells has become one of the intensively studied areas in cancer immunotherapy. However, fewer options targeting Treg cells have been validated in clinical trials and therefore more preclinical and clinical studies are required to provide reliable therapeutic targets with respect to Treg cell biology. To that end, this selection will highlight recent progresses in Treg cell biology and provide new opportunities for developing new therapeutic approaches to target Treg cells.
The scope and topics of this collection include but are not limited to:
The generation and accumulation of Treg cells in cancer host.
The regulatory function of Treg cells in shaping immune response to cancer.
The role of Treg cells in the prognosis of cancer and in response to immunotherapy.
Therapeutic targets in Treg cells that can promote antitumor immunity.